“flexus-biosciences” Archives

in
Entry Author Date Location
Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact 05/27/20 San Francisco
Bristol-Myers Latest to Drop IDO Studies in Wake of Incyte Failure 04/30/18 New York
Incyte, Merck Cancer Trial Failure Damages IDO Drugs’ Prospects 04/06/18 National
Tempest Therapeutics Debuts with $70M to Bring Cancer Drugs to Clinic 03/28/18 San Francisco
Arcus Bio Pulls Off IPO, Raises $120M for Cancer Immunotherapies 03/15/18 San Francisco
Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost 02/14/18 New York
Bio Roundup: Kite’s CAR-T Approved, Obamacare Fix & Lilly mRNA Deal 10/20/17 National
IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout 08/03/17 Boston
Bristol Flips Remnants of Adnexus, iPierian to Roche, Biogen For $470M 04/13/17 New York
East Coast Biotech Roundup: Sarepta, Nico, Ironwood & More 04/28/16 Boston
Taris 2.0: A Year After Buyout, VCs Bet $32M More on a Second Strike 10/27/15 Boston
Five Prime, Bristol Shake Hands Again in New $350M Cancer Pact 10/15/15 San Francisco
East Coast Biotech Roundup: Varmus, Bristol, Aerie, Aura & More 03/06/15 Boston
Tiger Teams, Dropping Subs, and Biotech’s Elusive Second Strikes 03/03/15 National
West Coast Biotech Roundup: Flexus, NGM, Illumina, Bob Klein & More 02/26/15 San Francisco
Yes to Flexus: The Science And Strategy Behind A Huge Biotech Return 02/26/15 San Francisco
Flexus Speeds From Inception to $1.25B Bristol Buyout In Less Than Two Years 02/23/15 San Francisco
Bristol-Meyers Squibb Acquires Flexus Biosciences for $1,250,000,000 02/23/15 San Francisco
West Coast Biotech Roundup: Gilead/AbbVie, Juno, Auspex, Bina & More 12/23/14 San Francisco
East Coast Biotech Roundup: Yumanity, Padlock, CAR-T Fever, & More 12/19/14 Boston
Flexus Biosciences Secures $38,000,000 Series B Financing 12/19/14 San Francisco
Page 1 of 1